General Western Blot Reagents
Abcam PRIMA-1MET, p53 activity, 25MG
MW 199.25 Da, Purity >98%. Methylated derivative of PRIMA-1 (ab141641). Restores wild-type conformation and function to mutant p53, and triggers apoptosis in tumor cells. Acts synergistically with chemotherapeutic agents to inhibit tumor cell proliferation. Inhibits thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance.
The product is subject to the following: Abcam Restricted Use Statement
Abcam (2S)-2-Hydro x yglutaric acid, alpha-ketoglutarate-dependent dio x ygenase competitive inhibitor, 25MG
MW 148.11 g/mol, Purity >95%. α-hydroxy acid. Normally metabolized to 2-oxoglutarate (α-ketoglutarate) by L-2-hydroxyglutarate dehydrogenases, and mutations in this enzyme cause L-2-hydroxyglutaric aciduria, a neurometabolic disorder. Structurally similar to α-ketoglutarate and competitively inhibits α-ketoglutarate-dependent dioxygenases, including lysine demethylases and DNA hydroxylases.
The product is subject to the following: Abcam Restricted Use Statement
Abcam NSC 3852, Histone deacetylase inhibitor, 50MG
MW 174.16 g/mol, Purity >95%. Histone deacetylase (HDAC) inhibitor. Causes cell differentiation and antiproliferative activity in MCF-7 human breast cancer cells in vitro and displays antitumor activity in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Gly-Phe beta-naphthylamide, Cathepsin C substrate, 1G
MW 347.41 g/mol, Purity >95%. Substrate for the lysosomal cysteine protease Cathepsin C. Accumulates within the lysosome. Hydrolysis by cathepsin C degrades Gly-Phe-β-naphthylamide into fragments that do not easily diffuse through the lysosomal membrane, leading to a loss of lysosome membrane integrity. Used to study intralysosomal hydrolysis, lysosomal membrane permeability, and the function of cathepsin C. Inhibits the cathepsin-dependent activation of caspase-8.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AG 555 (Tyrphostin B46), EGFR-tyrosine kinase inhibitor.
AG 555 (Tyrphostin B46), EGFR-tyrosine kinase inhibitor.
The product is subject to the following: Abcam Restricted Use Statement
Abcam MIRA-1, p53 inducer, 50MG
MW 183.16 Da, Purity >99%. Novel, nontoxic and selective p53 inducer. Antitumor agent. Promotes tumor cell apoptosis in a mutant p53-dependent manner (IC₅₀ = 10 μM) and prolongs survival. Active in vivo and in vitro.
The product is subject to the following: Abcam Restricted Use Statement
Abcam L-Mimosine, non-protein amino acid, 100MG
MW 198.18 g/mol, Purity >98%. Toxic non-protein amino acid originally isolated from Mimosa pudica. Arrests the cell cycle at the G1 phase in PC-3 cells and at the S phase in LNCaP cells, thus attenuating cell proliferation. Blocks cell cycle progression by chelating iron in asynchronous MDA-MB-453 human breast cancer cells. Arrests DNA synthesis by inhibiting deoxyribonucleotide metabolism. Prolyl hydroxylase (PHD) inhibitor stimulating VEGF production, and increasing proangiogenic capacity in dental pulp-derived cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam D-Fructose 6-phosphate disodium salt hydrate, Glycolytic intermediate, 500MG
MW 304.1 g/mol, Purity >98%. Sugar intermediate of the glycolytic pathway produced by the isomerization of glucose-6-phosphate by phosphoglucoisomerase.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 3-Cyano-7-etho x ycoumarin, Fluorogenic cytochrome P450 monoo x ygenase substrate, 100MG
MW 215.2 g/mol, Purity >99%. Fluoreogenic cytochrome P450 mixed-function monooxygenase substrate. Metabolized to the fluorescent compound 3-cyano-7-hydroxycoumarin. About 50-100 times more sensitive than conventional substrate ethoxy-resorufin due to higher turn over rate.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BHHCT, Fluorescent sensitizer for Eu3+- labelling, 1G
MW 804.9 Da, Purity >90%. Fluorescent sensitizer for Eu3+- labelling. Increases luminescence intensity 11 fold. Persists as an Eu3+ complex for 500 μs typical of the Eu3+ oxidation state. Measures peroxidase activity and oxidative stress levels.
The product is subject to the following: Abcam Restricted Use Statement
Abcam N-He x anoyl-L-homoserine lactone, involved in quorum sensing, 50MG
MW 199.3 g/mol, Purity >98%. Autoinducer involved in quorum sensing. Member of N-acyl-homoserine lactone (AHL) family that regulate gene expression in gram-negative bacteria and are involved in the processes of bacterial quorum sensing.
The product is subject to the following: Abcam Restricted Use Statement
Abcam PF 356231, MMP-12 inhibitor, 1MG
MW 428.5 Da, Purity >98%. Potent and selective non-chelating MMP-12 inhibitor (IC₅₀ = 14 nM). Inhibits other MMPs at higher concentrations. Inhibits cancer cell migration and invasion.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 5-CFDA N-succinimidyl ester, Fluorogenic esterase substrate.
5-CFDA N-succinimidyl ester, Fluorogenic esterase substrate.
The product is subject to the following: Abcam Restricted Use Statement
Abcam VAS 2870, NADPH o x idase inhibitor, 10MG
MW 360.4 g/mol, Purity >98%. NADPH oxidase inhibitor. Blocks PDGF-mediated NADPH activation and ROS production. Inhibits PMS-induced oxidative burst (IC₅₀ = 2 μM, HeLa cells). Shows anti-ischemic effects ex vivo. .
The product is subject to the following: Abcam Restricted Use Statement
Abcam Nonivamide, TRPV1 agonist, 1G
MW 293.4 Da, Purity >98%. TRPV1 agonist. Less potent Capsaicin (ab141000) analog. Induces Ca²+ release from ER. Blood-brain barrier permeable. Active in vivo.
The product is subject to the following: Abcam Restricted Use Statement